1. Ahmed D, Danielsen SA, Aagesen TH, Bretthauer M, Thiis-Evensen E, Hoff G, et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clin Translat Gastroenterol 2012;3:e27. [ DOI:10.1038/ctg.2012.21] 2. Jass J, Walsh M, Barker M, Simms L, Young J, Leggett B. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002;38:858-66. [ DOI:10.1016/S0959-8049(02)00041-2] 3. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 2018;9:402. [ DOI:10.3389/fendo.2018.00402] 4. Maajani K, Khodadost M, Fattahi A, Shahrestanaki E, Pirouzi A, Khalili F, et al. Survival rate of colorectal cancer in Iran: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2019;20:13. [ DOI:10.31557/APJCP.2019.20.1.13] 5. Shadmani FK, Ayubi E, Khazaei S, Sani M, Hanis SM, Khazaei S, et al. Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study. Epidemiol Health 2017;39. [ DOI:10.4178/epih.e2017020] 6. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619-25. [ DOI:10.1038/nm.3175] 7. Du S, Li Y, Sun H, Deng G, Tang S, Zeng F, et al. The risk of developing second primary malignancies among colorectal cancer patients. Aging (Albany NY) 2022;14:6756. [ DOI:10.18632/aging.204250] 8. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85. [ DOI:10.3390/ijms140816365] 9. Al‐Sohaily S, Biankin A, Leong R, Kohonen‐Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol 2012;27:1423-31. [ DOI:10.1111/j.1440-1746.2012.07200.x] 10. Hagland HR, Berg M, Jolma IW, Carlsen A, Søreide K. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg 2013;30:12-25. [ DOI:10.1159/000347166] 11. Prenen H, Tejpar S, Cutsem EV. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010;16:2921-6. [ DOI:10.1158/1078-0432.CCR-09-2029] 12. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, et al. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Ccancer 2015;15:1-9. [ DOI:10.1186/s12885-015-1345-3] 13. Hood FE, Sahraoui YM, Jenkins RE, Prior IA. Ras protein abundance correlates with Ras isoform mutation patterns in cancer. Oncogene 2023;42:1224-32. [ DOI:10.1038/s41388-023-02638-1] 14. Karkhane M, Lashgarian HE, Hormozi M, Fallahi S, Cheraghipour K, Marzban A. Oncogenesis and tumor inhibition by microRNAs and its potential therapeutic applications: a systematic review. MicroRNA 2020;9:198-215. [ DOI:10.2174/2211536608666191104103834] 15. Luo Q-q, Tian Y, Qu G-j, Luo S-s. Functional mechanism and clinical implications of miR-141 in human cancers. Cell Signal 2022;95:110354. [ DOI:10.1016/j.cellsig.2022.110354] 16. Hamzehzadeh L, Khadangi F, Karimiani EG, Pasdar A, Kerachian MA. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. Curr Probl Cancer 2018;42:572-81. [ DOI:10.1016/j.currproblcancer.2018.05.001] 17. Yari A, Afzali A, Aalipour M, Nakheai M, Zahedi MJ. KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian J Intern Med 2020;11:355. 18. Vega MYE. Con la esperanza de volver: mujeres migrantes de retorno a El Salvador. Anuario Americanista Europeo. 2013;11:165-77. 19. Yin J, Bai Z, Song J, Yang Y, Wang J, Han W, et al. Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chinese J Cancer Res 2014;26:95. 20. Ahadi A. The significance of microRNA deregulation in colorectal cancer development and the clinical uses as a diagnostic and prognostic biomarker and therapeutic agent. Non-coding RNA Res 2020;5:125-34. [ DOI:10.1016/j.ncrna.2020.08.003] 21. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS One 2011;6:e17745. [ DOI:10.1371/journal.pone.0017745] 22. Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y, et al. Serum miR-372 is a diagnostic and prognostic biomarker in patients with early colorectal cancer. Anticancer Agents Med Chem 2016;16:424-31. [ DOI:10.2174/1871520615666150716110406] |
